Bonanno, L.; Ronchi, A.; Bao, L.C.; Pante, F.; Sangiorgi, S.; Pasello, G.; Indraccolo, S.; Guarneri, V.
Anti-TROP2 Antibody Drug Conjugates in EGFR-Mutant Non-Small Cell Lung Cancer: Biological Rationale and Clinical Challenges. Pharmaceutics 2026, 18, 905.
https://doi.org/10.3390/pharmaceutics18080905
AMA Style
Bonanno L, Ronchi A, Bao LC, Pante F, Sangiorgi S, Pasello G, Indraccolo S, Guarneri V.
Anti-TROP2 Antibody Drug Conjugates in EGFR-Mutant Non-Small Cell Lung Cancer: Biological Rationale and Clinical Challenges. Pharmaceutics. 2026; 18(8):905.
https://doi.org/10.3390/pharmaceutics18080905
Chicago/Turabian Style
Bonanno, Laura, Alberto Ronchi, Loc Carlo Bao, Francesca Pante, Sara Sangiorgi, Giulia Pasello, Stefano Indraccolo, and Valentina Guarneri.
2026. "Anti-TROP2 Antibody Drug Conjugates in EGFR-Mutant Non-Small Cell Lung Cancer: Biological Rationale and Clinical Challenges" Pharmaceutics 18, no. 8: 905.
https://doi.org/10.3390/pharmaceutics18080905
APA Style
Bonanno, L., Ronchi, A., Bao, L. C., Pante, F., Sangiorgi, S., Pasello, G., Indraccolo, S., & Guarneri, V.
(2026). Anti-TROP2 Antibody Drug Conjugates in EGFR-Mutant Non-Small Cell Lung Cancer: Biological Rationale and Clinical Challenges. Pharmaceutics, 18(8), 905.
https://doi.org/10.3390/pharmaceutics18080905
